Skip to content

Stock-Based Comp at other companies

Abbott logo
AbbottABT
$317M+9.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$300M+4.2%
Boston Scientific logo
Boston ScientificBSX
$83M+12.2%
AtriCure logo
AtriCureATRC
$11.27M+17.1%
Medtronic logo
MedtronicMDT
$95M+6.7%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$8.96M-1.3%

Other financials

Income statement

See full
Revenue$401.0K
Gross profit$31.0K
Operating income-$19.2M-6.1%
Net income-$18.6M-10.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$68.3M-42.7%
Total debt$7.2M-16.6%
Total equity$66.3M-44.0%
Total assets$81.6M-38.8%

Cash flow

See full
Operating cash flow-$14.6M-7.9%
CapEx$33.0K-26.7%
Free cash flow-$14.6M-7.8%

Valuation

See full
Market cap$1.77B+38.4%

Profitability

See full
Gross margin-4,067.5%
Operating margin-10,392.1%
Net margin-9,929%
FCF margin-7,390%

Returns & leverage

See full
Return on equity-80.7%+3.1pp
Debt / equity0.1×0.0×
Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s stock-based comp?
Pulse Biosciences, Inc. (PLSE) reported stock-based comp of $1.91M in Q1 2026.
How has Pulse Biosciences, Inc.'s stock-based comp changed year-over-year?
Pulse Biosciences, Inc.'s stock-based comp decreased by 66.3% year-over-year, from $5.68M to $1.91M.
What is the long-term trend for Pulse Biosciences, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Pulse Biosciences, Inc.'s stock-based comp has grown at a 10.1% compound annual growth rate (CAGR), from $14.6M to $21.46M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.